Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ).
Shanghai Pharmaceuticals Holding Co., Ltd. has scheduled a board meeting for 29 April 2026 to review and approve the group’s first quarter results for the three months ended 31 March 2026. The move signals the forthcoming release of the company’s quarterly financial performance, which will provide investors and other stakeholders with updated visibility on its operating momentum and business conditions.
The announcement also reconfirms the current composition of the board, including executive, non-executive, employee, and independent non-executive directors led by chairman Yang Qiuhua. The board structure underscores the company’s established governance framework as it prepares to disclose its latest results to the market.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a China-based pharmaceutical group engaged in the manufacture, distribution, and retail of medicines and healthcare products. Listed in Hong Kong, the company operates through a network of subsidiaries, serving hospitals, pharmacies, and broader medical markets across the mainland.
Average Trading Volume: 2,314,141
Technical Sentiment Signal: Buy
Current Market Cap: HK$66.12B
For an in-depth examination of 2607 stock, go to TipRanks’ Overview page.